News about University Research Park tenants.

Quintessence Biosciences Cancer Drug, QBI-139, Clears FDA Review to Start Phase I Human Trial
December 5, 2008
MADISON, WISCONSIN- December 5, 2008 - Quintessence Biosciences, Inc. announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for the first of the Company's EVade(tm) Ribonuclease drug candidates, called QBI-139. The Company will begin a Phase I trial of QBI-139 in patients with solid tumors in the coming months.

---

Cellular Dynamics International Merges companies, closes on $18 Million Financing
November 24, 2008
MADISON, Wis., November 24, 2008 - Cellular Dynamics International (CDI) announced today the merger of sister companies Stem Cell Products Inc. and iPS Cells Inc. with CDI. The merged entity will continue to operate as Cellular Dynamics International, Inc. (CDI). The merger positions CDI as a leader in the stem cell research tools and personalized bio-banking industries by placing the intellectual property and commercial, research, and production capabilities of the predecessor companies under a unified management team.

---

Roche NimbleGen, Inc. Participates in Madison’s Inaugural Roche Children’s Walk; the First Step to a Cure
November 17, 2008
Roche NimbleGen 5k walk/run through Research Park to raise funds to help children in our own backyard and around the world. On December 1st for the sixth consecutive year, Roche, and now Roche NimbleGen, will be holding a sponsored worldwide walk to raise money to help vulnerable children and orphans both locally and globally.

---

Preschool of the Arts welcomes new Executive Director
October 30, 2008
Preschool of the Arts, Madison’s only preschool inspired by the Reggio approach, is pleased to announce its new Executive Director, Brian Crisp.

---

Accelerate Madison Webcast
October 15, 2008
"Is Madison's TECHNOLOGY COMMUNITY at a TIPPING POINT?" Best Practices and Solid Ideas for High-Growth Enterprises & Entrepreneurs.

---

Stratatech completes clinical trial of skin substitute
September 29, 2008
Madison, Wis. - Stratatech Corp. has announced the successful completion of a clinical trial of its StrataGraft human skin substitute. The company, a regenerative medicine company focused on the commercialization of tissue-engineered skin substitutes, said it achieved its primary clinical endpoint for the trial, which is engraftment that is comparable to the standard of care.

---

Primorigen Biosciences LLC Receives Phase I SBIR Grant
September 2, 2008
Madison, WI. Primorigen Biosciences LLC has announced that is has received a Phase I SBIR grant of $362,714 from the National Institutes of Health Center for Research Resources, thus qualifying the company to compete for an additional $1.6 M. grant at the end of Phase I studies.

---